Clinical Trial Search

Primary: To Determine Percent of Excess Weight Loss (%EWL) After Laparoscopic Adjustable Gastric Banding Surgery — 51.74 percentage of excess weight loss

Primary: Size of Adipocytes — 73.4; 99.0; 103.0 µm

Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year

Primary: DEXA-measured Adiposity — 0.76; -0.43; -2.79 kilograms — p=0.01

Primary: Proportion of Potential Participants Who Are Eligible. — 0.95 Proportion

Primary: Diagnosis of Infectious Disease — 900; 1067 Participants — p=.026

Primary: Relative Change in Body Weight (%) — -0.33; 0.38 Percentage of body weight change

Primary: Negative Affect — 1.43; 1.29 score on a scale — p=.007

Primary: Total Clearance of Ethambutol — 80.8 L/h

Primary: Part 1: Percent Change in Body Weight From Baseline to Week 12 — -5.51; 0.19; -6.55; 0.29 percent change — p=<0.001

Primary: Gestational Weight Gain (GWG) — 12; 10 kg — p=0.01

Primary: LNG Steady State at Baseline and Then Post-randomization — 3.82; 3.13; 3.01; 3.58 ng/mL

Primary: Luteinizing Hormone Pulse Amplitude — 2.73; 1.12 IU/L

Primary: Adverse Event Frequency — 11; 11; 1; 0 Participants

Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05

Primary: Fat Mass — 44.71 Kg

Primary: Cesarean Section

Primary: Maternal Weight Change — 1.2; -2.6 kg

Primary: Resting Energy Expenditure After 12 Weeks of Drug Therapy (kcal/Day) — 1267; 1268 kcal/day

Primary: Maternal Visceral Adipose Tissue Volume — 97593; 169626; 96787 mm3

Primary: Change in Child Self-report Health Related Quality of Life Scores After Intervention: Total, Physical and Psychosocial (Presented in This Order) — 7.8; -0.9; 9.1; -0.3…

Primary: Feasibility - Number of Enrolled Participants — 38 Participants

Primary: Change in Energy Intake From Baseline — 500; 310; 482; 5 kcal

Primary: Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8 — -12.1; -6.8 mm Hg

Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) — 167.0; 168.2; 138.9; 151.6 mm Hg

Primary: Proportion of Patients Triaged to the Low Risk Weight Management Clinics — 28 Participants

Primary: Clearance (Cl) for Doxorubicin and Cyclophosphamide — 1.85 L/hr

Primary: Change in Bodyweight — -7.4; -6.1 percentage of bodyweight change — p=0.196

Primary: Percent of Subjects Attaining Clinically Successful Weight Loss ( ≥ 30% EWL) at 1 Year Post LAP-BAND Implantation — 83.9 percentage of subjects

Primary: Success Rate of Biochemical Resolution of Diabetes at 12 Months as Measured by HbA1c ≤ 6%. — 5; 21; 18 participants — p=0.002